Nl-Fr

View abstract

This abstract is assigned to session OB Free papers 4 - Glaucoma
TitleFRO - Can peroperative bevacizumab (Avastin) improve trabeculectomy outcome? A prospective, randomized, placebo-controlled study
PurposeGlaucoma surgery fails in 30% due to excessive scar formation of the constructed channel. Our group found that vascular endothelial growth factor (VEGF) is upregulated in the aqueous humor of glaucoma patients and postoperatively in a rabbit model for trabeculectomy, that VEGF stimulates fibroblast proliferation in vitro whereas bevacizumab can inhibit their growth, and that a single peroperative intracameral injection of bevacizumab improves the surgical outcome of trabeculectomy in a rabbit model. Based on these findings, we set up a clinical trial to study the potential of bevacizumab as an anti-scarring agent after trabeculectomy.
MethodsThis is a prospective, randomized, placebo-controlled, double-blinded experimental study. The effect of peroperative administration of 50 µl of bevacizumab (25mg/ml) on intraocular pressure, bleb characteristics, as well as number of postoperative IOP-lowering medications and surgical interventions is investigated. Patients with primary open-angle glaucoma (POAG) and normal tension glaucoma (NTG) who are scheduled for primary trabeculectomy are included.
ResultsInclusions started on April 2009. Based on a priori calculations we need to include 124 patients. The inclusions will be accomplished in September 2010.
ConclusionThis study will provide evidence on effectiveness and safety of single administration of bevacizumab during trabeculectomy to reduce the risk of surgical failure, avoiding or reducing the need for long-term medication use or secondary surgical intervention.
Author 1
Last nameVANDEWALLE
InitialsE
DepartmentULZ
CityLeuven
Author 2
Last nameZeyen
InitialsT
DepartmentUZL
CityLeuven
Author 3
Last nameSpielberg
InitialsI
DepartmentDep of ophthalmology
CityRotterdam
Author 4
Last nameStalmans
InitialsI
DepartmentUZL
CityLeuven
top ^